Whitfill plans to share initial data from the ATR-COSF program, which utilizes a microbial genetic engineering platform to target cosmetic concerns like fine lines and wrinkles. His update will also cover ongoing enrollment for the first cohort of the Phase 1/2 clinical trial testing ATR-04, an investigational treatment for EGFR inhibitor-associated rash. This condition currently affects approximately 150,000 people in the United States, and the therapy has already secured FDA Fast Track designation.
Azitra to Detail Dermatology Pipeline at H.C. Wainwright Conference
Travis Whitfill, co-founder and chief operating officer of the biopharmaceutical firm Azitra, will present the company’s latest clinical progress at the H.C. Wainwright 28th Annual Global Investment Conference in New York. The virtual presentation, scheduled for September 14-16, will outline advancements across the company's precision dermatology and cosmetic protein portfolios.
Beyond the prerecorded presentation, Whitfill will engage in one-on-one meetings with investors and potential partners to discuss corporate strategy, recent achievements, and upcoming milestones. Azitra continues to integrate its proprietary microbial library with artificial intelligence to develop specialized products for consumer, research, and healthcare markets.
Comments (0)
No comments yet. Be the first!